Homology Medicines Reports First Quarter 2023 Financial Resu

- On Track to Report Initial Clinical Data from pheEDIT PKU Gene Editing Trial Mid-Year 2023 - - First Presentations of Preclinical Data with GTx-mAb Development Candidate HMI-104 for PNH, and... | May 11, 2023

Related Keywords

United States , Cara Mayfield , Albert Seymour , Slattery Jr , Oxford Biomedica , American Society Of Gene Cell Therapy , Exchange Commission , Corporate Communications , Nasdaq , Company Contacts , Homology Medicines Inc , Securities Exchange , Pfizer , World Orphan Drug Congress United States , Globenewswire Inc , Company Stock Purchase Agreement , Report Initial Clinical Data , Editing Trial , Preclinical Data , Financial Position , Anticipated Cash Runway , Fourth Quarter , Chief Executive Officer , Cell Therapy , Annual Meeting , Stock Purchase Agreement , Orphan Drug Congress United States , Homology Medicines , Securities Act , Securities Exchange Act , Quarterly Report , Tables Follow , Nc Stock Exchange , News , Information , Press Release , N , Track , O , Report , Nitial , Linical , Data , Rom , Heedit , Oku , Gene , Editing , 023 , First , Presentations , F , Reclinical , Ith , Development , Candidate , Or Fixx Us4380831077 ,